 Rasa Kazlauskaite
Concepts (259)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Women's Health | 14 | 2021 | 247 | 1.800 |
Why?
| | Adiposity | 8 | 2018 | 54 | 1.580 |
Why?
| | Menopause | 9 | 2021 | 131 | 1.560 |
Why?
| | Intra-Abdominal Fat | 6 | 2021 | 48 | 1.380 |
Why?
| | Obesity | 6 | 2018 | 359 | 1.200 |
Why?
| | Diabetes Mellitus, Type 2 | 6 | 2015 | 230 | 1.110 |
Why?
| | Cardiovascular Diseases | 8 | 2021 | 446 | 1.010 |
Why?
| | Ecosystem | 1 | 2023 | 27 | 0.960 |
Why?
| | Diabetes Mellitus | 2 | 2023 | 160 | 0.930 |
Why?
| | Thrombosis | 2 | 2014 | 74 | 0.900 |
Why?
| | Obesity, Abdominal | 4 | 2015 | 23 | 0.880 |
Why?
| | Middle Aged | 36 | 2021 | 11219 | 0.840 |
Why?
| | Adrenal Gland Diseases | 2 | 2012 | 3 | 0.800 |
Why?
| | Atrial Fibrillation | 2 | 2014 | 234 | 0.740 |
Why?
| | Female | 43 | 2021 | 18423 | 0.720 |
Why?
| | Abdominal Fat | 3 | 2021 | 12 | 0.710 |
Why?
| | Diet Therapy | 1 | 2018 | 11 | 0.690 |
Why?
| | Weight Reduction Programs | 1 | 2018 | 18 | 0.670 |
Why?
| | Atherosclerosis | 3 | 2021 | 78 | 0.640 |
Why?
| | Behavior Therapy | 1 | 2018 | 90 | 0.640 |
Why?
| | Exercise Therapy | 1 | 2018 | 119 | 0.630 |
Why?
| | Humans | 47 | 2023 | 32988 | 0.620 |
Why?
| | Risk Factors | 20 | 2021 | 2762 | 0.620 |
Why?
| | Testosterone | 2 | 2014 | 35 | 0.620 |
Why?
| | Hydrocortisone | 3 | 2012 | 55 | 0.620 |
Why?
| | Waist-Height Ratio | 1 | 2016 | 6 | 0.610 |
Why?
| | Metabolic Diseases | 1 | 2016 | 16 | 0.600 |
Why?
| | Adult | 22 | 2021 | 9848 | 0.560 |
Why?
| | United States | 15 | 2021 | 2632 | 0.560 |
Why?
| | Mass Screening | 1 | 2016 | 203 | 0.520 |
Why?
| | Cognition Disorders | 2 | 2020 | 1061 | 0.490 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2014 | 55 | 0.480 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2013 | 12 | 0.470 |
Why?
| | Adrenal Cortex Function Tests | 1 | 2012 | 1 | 0.460 |
Why?
| | Hemodynamics | 1 | 2012 | 100 | 0.440 |
Why?
| | Prevalence | 4 | 2016 | 554 | 0.440 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2009 | 10 | 0.440 |
Why?
| | Postmenopause | 6 | 2019 | 67 | 0.440 |
Why?
| | Liver Cirrhosis | 1 | 2012 | 61 | 0.430 |
Why?
| | Lipoproteins, HDL | 3 | 2014 | 31 | 0.420 |
Why?
| | Blood Glucose Self-Monitoring | 2 | 2009 | 6 | 0.420 |
Why?
| | Carotid Intima-Media Thickness | 2 | 2021 | 24 | 0.420 |
Why?
| | Perimenopause | 3 | 2021 | 24 | 0.400 |
Why?
| | Longitudinal Studies | 9 | 2020 | 1485 | 0.390 |
Why?
| | Diastole | 1 | 2010 | 35 | 0.380 |
Why?
| | Absorptiometry, Photon | 3 | 2015 | 82 | 0.380 |
Why?
| | Follow-Up Studies | 9 | 2020 | 2053 | 0.380 |
Why?
| | Adrenal Insufficiency | 1 | 2009 | 7 | 0.380 |
Why?
| | Vitamin D | 1 | 2010 | 34 | 0.370 |
Why?
| | Cardiomyopathies | 1 | 2010 | 38 | 0.370 |
Why?
| | Blood Glucose | 5 | 2020 | 135 | 0.360 |
Why?
| | Pituitary Diseases | 1 | 2008 | 3 | 0.340 |
Why?
| | Hypothalamic Diseases | 1 | 2008 | 6 | 0.340 |
Why?
| | Reproducibility of Results | 4 | 2014 | 893 | 0.330 |
Why?
| | Algorithms | 3 | 2023 | 428 | 0.330 |
Why?
| | Hypertension | 4 | 2021 | 293 | 0.320 |
Why?
| | Body Mass Index | 5 | 2018 | 478 | 0.320 |
Why?
| | Socioeconomic Factors | 4 | 2023 | 364 | 0.310 |
Why?
| | Population Surveillance | 2 | 2020 | 126 | 0.310 |
Why?
| | Prospective Studies | 6 | 2020 | 2002 | 0.310 |
Why?
| | Depression | 3 | 2018 | 533 | 0.300 |
Why?
| | Sensitivity and Specificity | 3 | 2014 | 592 | 0.290 |
Why?
| | Cohort Studies | 7 | 2020 | 2077 | 0.290 |
Why?
| | Exercise | 3 | 2018 | 494 | 0.290 |
Why?
| | Ketone Bodies | 1 | 2005 | 5 | 0.280 |
Why?
| | Prognosis | 3 | 2020 | 1011 | 0.280 |
Why?
| | Risk Assessment | 3 | 2020 | 814 | 0.270 |
Why?
| | Male | 13 | 2020 | 17726 | 0.260 |
Why?
| | ROC Curve | 3 | 2009 | 155 | 0.260 |
Why?
| | Incidence | 5 | 2020 | 840 | 0.260 |
Why?
| | Economic Development | 1 | 2023 | 4 | 0.250 |
Why?
| | Estradiol | 4 | 2021 | 61 | 0.250 |
Why?
| | Developing Countries | 1 | 2023 | 24 | 0.250 |
Why?
| | Pregnanediol | 2 | 2021 | 6 | 0.250 |
Why?
| | Luteinizing Hormone | 2 | 2021 | 12 | 0.250 |
Why?
| | Pharmacoepidemiology | 2 | 2020 | 5 | 0.240 |
Why?
| | Insulin | 2 | 2011 | 117 | 0.240 |
Why?
| | Diet | 2 | 2019 | 228 | 0.240 |
Why?
| | Chicago | 5 | 2014 | 957 | 0.240 |
Why?
| | Life Style | 2 | 2018 | 226 | 0.230 |
Why?
| | Energy Intake | 3 | 2019 | 99 | 0.230 |
Why?
| | Atrial Appendage | 2 | 2014 | 53 | 0.230 |
Why?
| | Waist Circumference | 4 | 2016 | 37 | 0.230 |
Why?
| | Hypoglycemic Agents | 1 | 2003 | 70 | 0.230 |
Why?
| | Energy Metabolism | 2 | 2018 | 82 | 0.220 |
Why?
| | Stroke Volume | 2 | 2014 | 67 | 0.210 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2018 | 320 | 0.210 |
Why?
| | Menstrual Cycle | 2 | 2021 | 29 | 0.210 |
Why?
| | Aged | 11 | 2020 | 10542 | 0.210 |
Why?
| | Hyperglycemia | 2 | 2020 | 48 | 0.210 |
Why?
| | Progesterone | 1 | 2021 | 29 | 0.200 |
Why?
| | Cosyntropin | 2 | 2012 | 3 | 0.200 |
Why?
| | Carotid Artery Diseases | 1 | 2021 | 55 | 0.200 |
Why?
| | Insulin Resistance | 4 | 2011 | 72 | 0.190 |
Why?
| | Cholesterol, HDL | 3 | 2011 | 32 | 0.190 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2020 | 115 | 0.190 |
Why?
| | Seasons | 1 | 2019 | 35 | 0.180 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 86 | 0.180 |
Why?
| | Cerebral Hemorrhage | 1 | 2020 | 151 | 0.170 |
Why?
| | Appetite | 1 | 2018 | 5 | 0.170 |
Why?
| | Antidepressive Agents | 1 | 2019 | 107 | 0.170 |
Why?
| | Fractures, Bone | 1 | 2019 | 72 | 0.170 |
Why?
| | Antihypertensive Agents | 1 | 2019 | 93 | 0.170 |
Why?
| | Weight Gain | 1 | 2018 | 75 | 0.160 |
Why?
| | Body Weight | 1 | 2018 | 167 | 0.160 |
Why?
| | Chronic Disease | 1 | 2020 | 554 | 0.160 |
Why?
| | Weight Loss | 1 | 2018 | 116 | 0.160 |
Why?
| | Hormones | 1 | 2017 | 18 | 0.160 |
Why?
| | Genetic Predisposition to Disease | 2 | 2018 | 467 | 0.150 |
Why?
| | Depressive Disorder | 1 | 2018 | 208 | 0.150 |
Why?
| | Beverages | 1 | 2016 | 13 | 0.150 |
Why?
| | Social Support | 1 | 2018 | 226 | 0.150 |
Why?
| | Time Factors | 4 | 2020 | 1873 | 0.150 |
Why?
| | Climacteric | 1 | 2015 | 10 | 0.140 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 626 | 0.140 |
Why?
| | Cross-Sectional Studies | 3 | 2009 | 1058 | 0.140 |
Why?
| | Estrogens | 1 | 2015 | 33 | 0.140 |
Why?
| | False Positive Reactions | 1 | 2015 | 38 | 0.140 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 23 | 0.140 |
Why?
| | Retrospective Studies | 5 | 2014 | 3835 | 0.140 |
Why?
| | Immunoassay | 1 | 2015 | 47 | 0.140 |
Why?
| | Carbonated Beverages | 1 | 2014 | 2 | 0.130 |
Why?
| | Child | 3 | 2009 | 1634 | 0.130 |
Why?
| | Waist-Hip Ratio | 1 | 2014 | 16 | 0.130 |
Why?
| | Research Report | 1 | 2014 | 11 | 0.130 |
Why?
| | Sweetening Agents | 1 | 2014 | 9 | 0.130 |
Why?
| | Birth Weight | 1 | 2015 | 46 | 0.130 |
Why?
| | Meals | 1 | 2014 | 15 | 0.130 |
Why?
| | Carcinoma, Ductal, Breast | 2 | 2015 | 36 | 0.130 |
Why?
| | Age Factors | 3 | 2020 | 932 | 0.130 |
Why?
| | Illinois | 2 | 2013 | 267 | 0.130 |
Why?
| | Hyperandrogenism | 1 | 2014 | 2 | 0.130 |
Why?
| | Oligomenorrhea | 1 | 2014 | 2 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 3 | 2014 | 899 | 0.130 |
Why?
| | Self Report | 3 | 2020 | 245 | 0.120 |
Why?
| | Echocardiography, Transesophageal | 1 | 2014 | 53 | 0.120 |
Why?
| | Body Image | 1 | 2014 | 37 | 0.120 |
Why?
| | Personal Satisfaction | 1 | 2014 | 57 | 0.120 |
Why?
| | Employment | 1 | 2013 | 46 | 0.120 |
Why?
| | Heart Valve Diseases | 1 | 2013 | 33 | 0.120 |
Why?
| | Body Fat Distribution | 1 | 2012 | 12 | 0.110 |
Why?
| | Blood Pressure | 4 | 2019 | 270 | 0.110 |
Why?
| | Logistic Models | 3 | 2019 | 474 | 0.110 |
Why?
| | Motor Activity | 2 | 2018 | 391 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2012 | 216 | 0.110 |
Why?
| | Ultrasonography | 1 | 2013 | 215 | 0.110 |
Why?
| | Up-Regulation | 1 | 2012 | 225 | 0.100 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 387 | 0.100 |
Why?
| | Subcutaneous Fat, Abdominal | 1 | 2011 | 2 | 0.100 |
Why?
| | Neuropsychological Tests | 2 | 2021 | 1306 | 0.100 |
Why?
| | Calcifediol | 1 | 2010 | 2 | 0.100 |
Why?
| | 25-Hydroxyvitamin D 2 | 1 | 2010 | 3 | 0.100 |
Why?
| | Metyrapone | 1 | 2009 | 1 | 0.090 |
Why?
| | Glucose Tolerance Test | 1 | 2009 | 11 | 0.090 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2010 | 48 | 0.090 |
Why?
| | Particle Size | 1 | 2010 | 81 | 0.090 |
Why?
| | Breast Neoplasms | 2 | 2015 | 435 | 0.090 |
Why?
| | Pericardium | 1 | 2010 | 30 | 0.090 |
Why?
| | Reference Standards | 1 | 2009 | 36 | 0.090 |
Why?
| | Antimetabolites | 1 | 2009 | 15 | 0.090 |
Why?
| | Infant | 2 | 2009 | 661 | 0.090 |
Why?
| | Alcohol Drinking | 1 | 2010 | 88 | 0.090 |
Why?
| | Follicle Stimulating Hormone | 2 | 2021 | 25 | 0.090 |
Why?
| | Child, Preschool | 2 | 2009 | 798 | 0.090 |
Why?
| | Hospitals, Public | 1 | 2009 | 30 | 0.090 |
Why?
| | Aged, 80 and over | 3 | 2018 | 5249 | 0.090 |
Why?
| | Regression Analysis | 1 | 2010 | 326 | 0.090 |
Why?
| | Health Behavior | 1 | 2010 | 181 | 0.090 |
Why?
| | Fasting | 1 | 2008 | 27 | 0.080 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2008 | 30 | 0.080 |
Why?
| | Urban Population | 1 | 2009 | 164 | 0.080 |
Why?
| | Glucocorticoids | 1 | 2008 | 80 | 0.080 |
Why?
| | Hypercalcemia | 1 | 2007 | 12 | 0.080 |
Why?
| | Burns | 1 | 2007 | 26 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2012 | 1242 | 0.080 |
Why?
| | Carotid Arteries | 2 | 2021 | 62 | 0.070 |
Why?
| | Linear Models | 2 | 2018 | 275 | 0.070 |
Why?
| | Patient Education as Topic | 1 | 2007 | 193 | 0.070 |
Why?
| | Adolescent | 2 | 2009 | 2687 | 0.070 |
Why?
| | Lamin Type A | 1 | 2004 | 2 | 0.060 |
Why?
| | Lipodystrophy | 1 | 2004 | 2 | 0.060 |
Why?
| | Acyltransferases | 1 | 2004 | 4 | 0.060 |
Why?
| | GTP-Binding Protein gamma Subunits | 1 | 2004 | 3 | 0.060 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2007 | 233 | 0.060 |
Why?
| | Intensive Care Units | 1 | 2007 | 339 | 0.060 |
Why?
| | Polymorphism, Genetic | 1 | 2004 | 90 | 0.060 |
Why?
| | Gluconeogenesis | 1 | 2003 | 4 | 0.060 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2003 | 11 | 0.060 |
Why?
| | Odds Ratio | 2 | 2015 | 321 | 0.060 |
Why?
| | Hyperlipidemias | 1 | 2003 | 26 | 0.060 |
Why?
| | Fatty Acids | 1 | 2003 | 47 | 0.060 |
Why?
| | Triglycerides | 2 | 2014 | 56 | 0.060 |
Why?
| | Young Adult | 1 | 2009 | 2287 | 0.060 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2014 | 376 | 0.060 |
Why?
| | Pulse Wave Analysis | 1 | 2021 | 4 | 0.050 |
Why?
| | Ankle Brachial Index | 1 | 2021 | 7 | 0.050 |
Why?
| | Liver | 1 | 2003 | 213 | 0.050 |
Why?
| | Patient Selection | 1 | 2003 | 261 | 0.050 |
Why?
| | Vasomotor System | 1 | 2021 | 5 | 0.050 |
Why?
| | Affect | 1 | 2021 | 71 | 0.050 |
Why?
| | Morbidity | 1 | 2020 | 72 | 0.050 |
Why?
| | Cognition | 1 | 2009 | 1325 | 0.050 |
Why?
| | Hypertriglyceridemia | 2 | 2014 | 25 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2003 | 388 | 0.050 |
Why?
| | Disease Progression | 1 | 2003 | 870 | 0.050 |
Why?
| | Diet Surveys | 1 | 2019 | 27 | 0.050 |
Why?
| | Propensity Score | 1 | 2019 | 56 | 0.040 |
Why?
| | Osteoporosis | 1 | 2019 | 79 | 0.040 |
Why?
| | Genetic Testing | 1 | 2018 | 77 | 0.040 |
Why?
| | Accidental Falls | 1 | 2019 | 118 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2018 | 358 | 0.040 |
Why?
| | Corpus Luteum | 1 | 2017 | 3 | 0.040 |
Why?
| | Estrone | 1 | 2017 | 6 | 0.040 |
Why?
| | Premenopause | 1 | 2017 | 22 | 0.040 |
Why?
| | Hospitalization | 1 | 2020 | 367 | 0.040 |
Why?
| | Genome-Wide Association Study | 1 | 2018 | 305 | 0.040 |
Why?
| | Genotype | 1 | 2018 | 422 | 0.040 |
Why?
| | Sleep | 1 | 2020 | 388 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2015 | 26 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2015 | 28 | 0.030 |
Why?
| | E-Selectin | 1 | 2015 | 3 | 0.030 |
Why?
| | Receptors, Estrogen | 1 | 2015 | 63 | 0.030 |
Why?
| | Androgens | 1 | 2014 | 8 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2015 | 386 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2015 | 694 | 0.030 |
Why?
| | Myocardial Infarction | 1 | 2014 | 194 | 0.030 |
Why?
| | Tunica Intima | 1 | 2011 | 32 | 0.030 |
Why?
| | Nutrition Policy | 1 | 2010 | 12 | 0.020 |
Why?
| | France | 1 | 2010 | 40 | 0.020 |
Why?
| | Vegetables | 1 | 2010 | 23 | 0.020 |
Why?
| | Dietary Fats | 1 | 2010 | 42 | 0.020 |
Why?
| | Fruit | 1 | 2010 | 30 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2010 | 78 | 0.020 |
Why?
| | Cross-Cultural Comparison | 1 | 2010 | 45 | 0.020 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2009 | 15 | 0.020 |
Why?
| | Biological Availability | 1 | 2009 | 26 | 0.020 |
Why?
| | Stroke | 1 | 2014 | 405 | 0.020 |
Why?
| | Aging | 1 | 2018 | 1634 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2010 | 368 | 0.020 |
Why?
| | Albumins | 1 | 2007 | 34 | 0.020 |
Why?
| | Cholesterol, LDL | 1 | 2007 | 46 | 0.020 |
Why?
| | Knowledge | 1 | 2007 | 24 | 0.020 |
Why?
| | Lipids | 1 | 2007 | 57 | 0.020 |
Why?
| | Length of Stay | 1 | 2007 | 382 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2015 | 4036 | 0.020 |
Why?
| | 1-Acylglycerol-3-Phosphate O-Acyltransferase | 1 | 2004 | 1 | 0.020 |
Why?
| | Consanguinity | 1 | 2004 | 4 | 0.020 |
Why?
| | RNA Splice Sites | 1 | 2004 | 3 | 0.020 |
Why?
| | Hyperinsulinism | 1 | 2004 | 5 | 0.020 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2004 | 15 | 0.020 |
Why?
| | Pennsylvania | 1 | 2004 | 15 | 0.020 |
Why?
| | Frameshift Mutation | 1 | 2004 | 7 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2004 | 48 | 0.020 |
Why?
| | Exons | 1 | 2004 | 42 | 0.020 |
Why?
| | Homozygote | 1 | 2004 | 29 | 0.020 |
Why?
| | Haplotypes | 1 | 2004 | 62 | 0.020 |
Why?
| | Alleles | 1 | 2004 | 231 | 0.020 |
Why?
| | Calcium | 1 | 2007 | 531 | 0.010 |
Why?
| | Phenotype | 1 | 2004 | 385 | 0.010 |
Why?
|
|
Kazlauskaite's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|